Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections (Q24239978)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

title

Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

invasive fungal infections

18 January 2020

main subject

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Katherine Hale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Pamela Palasanthiran

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Tracey O'Brien

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Michael H Bennett

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

17 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

CD006343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20166083%20AND%20SRC:MED&resulttype=core&format=json

Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Use of amphotericin B colloidal dispersion in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever — preliminary observations from a pilot, exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Pharmacokinetics of amphotericin B in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Systemic antifungal drugs for invasive fungal infection in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

The epidemiology of sepsis in the United States from 1979 through 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Combination treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Pediatric aspergillosis: disease and treatment differences in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

New antifungal agents under development in children and neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

Pharmacokinetics of fluconazole in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

7 January 2021

Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

7 January 2021

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006343.PUB2

7 January 2021